Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01129570 · ClinicalTrials.gov registry record · Phase 1

Siliphos in Advanced Hepatocellular Carcinoma

A Phase 1 study of Advanced Hepatocellular Carcinoma, sponsored by Abby Siegel.

Completed
Registry status
Phase 1
Development phase
3
Enrollment target
1
Study location

NCT01129570: Completed Phase 1 study of Advanced Hepatocellular Carcinoma, sponsored by Abby Siegel.

NCT01129570 is a Phase 1 study of Advanced Hepatocellular Carcinoma that has completed, run by Abby Siegel. The registered enrollment target is 3 participants, below the 87-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01129570, a Phase 1 study of Advanced Hepatocellular Carcinoma, has completed, sponsored by Abby Siegel.

COMPLETED
Registry status
Phase 1
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States. It has not been used in patients with liver cancer previously, to our knowledge, but there have been many studies of its use in patients with hepatitis and cirrhosis. Some of these studies have shown that milk thistle may help reduce elevated liver function tests. Siliphos is a derivative of milk thistle that can be absorbed better than some other types of milk thistle. The investigators would like to perform a study to identify doses of siliphos that are safe to take in advanced liver cancer and to identify positive or negative side effects this compound may have. The investigators will be using this information in future studies to see if siliphos can be used as a therapy in patients with advanced liver cancer to reduce elevated liver function tests.

Conditions Studied

Advanced Hepatocellular Carcinoma

Interventions

  • DRUG Silybin

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2010-02
Est. Completion 2013-06
Phase Phase 1
Abby Siegel

1 total trials

What the finished NCT01129570 record still lists

NCT01129570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 87-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Silybin is the first listed.

NCT01129570 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01129570 about?

NCT01129570 is a clinical study titled "Siliphos in Advanced Hepatocellular Carcinoma". Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States. It has not been used in...

What is the current status of trial NCT01129570?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2010-02. Estimated completion is 2013-06.

What conditions does trial NCT01129570 study?

This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.

What interventions are being tested in trial NCT01129570?

The interventions under investigation include: Silybin (DRUG).

Who is sponsoring clinical trial NCT01129570?

This trial is sponsored by Abby Siegel, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01129570 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01129570's enrollment target sits among peer trials

3 17th of 16 the lowest of 16 other Advanced Hepatocellular Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01129570, the US trial registry maintained by the National Library of Medicine. NCT01129570 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.